Clinical Trials: Non-Hodgkin's Lymphoma

Phase I Trial of Radioimmunotherapy of Relapsed or Refractory Non-Hodgkin's Lymphoma with ⁹⁰Yttrium-Labeled Humanized LL2 IgG Antibody

This is a non-randomized, Phase I trial study to administer yttrium-90 radioisotope-labeled, humanized LL2 anti-CD22 antibody to advanced non-Hodgkin's lymphoma patients who are resistant to other forms of treatment or who have recurrent disease. The dose-escalation study is designed to evaluate the safety, tolerance, maximum tolerated dose (MTD), and potential anti-tumor effects of the treatment procedure.

Who is eligible for this study?

1. Patients must have a histologic or cytologic diagnosis of non-Hodgkin's lymphoma of either indolent or aggressive histologies with immunohistologic evidence of CD22 target antigen expression.
2. Patients must have failed one regimen of standard chemotherapy.
3. Patients must have adequate blood cell counts and adequate liver, kidney, heart and lung functions.
4. For further information as to the inclusion/exclusion criteria contact Clare Machado, MD (973)-844-7113 or email to: cmachado@gscancer.org